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plantation (HSCT) is indicated for patients with intermediate
or high risk primary Myeloﬁbrosis (MF), and also in patients
with Policitemia Vera or Essential Thrombocythemia who
have progressed to high risk MF. The results for allogeneic
HSCT with myeloablative conditioning seem to be better for
patients younger than 45 years, determining lower relapse
risk. However, Reduced Intensity Conditioning (RIC) for
patients between 45 and 65 years-old has shown to be
a promising strategy, with less mortality related to the
procedure. This study aims describing a series of patients
diagnosed with myeloﬁbrosis, transplanted in the Hospital
de Clínicas (HC) from the Federal University of Paraná and
Hospital Nossa Senhora das Graças (HNSG) (Curitiba, Brazil).
Patients and Methods: From 1984 to 2011, fourteen patients
with MF were submitted to HSCT, eleven from the HC and
three from HNSG. The median of age was 42 years (10-51).
Therewere ten males and four females. In average, ﬁve blood
transfusions were done per patient (0-61). Five male patients
received the graft from a female donor, and two patients
received an unrelated HSCT. The median of duration of the
disease was 20 months (2-150). According to Dupriez Clas-
siﬁcation, all the patients were of intermediate and high risk.
Five patients had a myeloablative conditioning (Busulfan
plus Cyclophosphamide: 4; Cyclophosphamide plus Total
Body Irradiation:1) while nine had a RIC transplant (Fludar-
abine 150mg/m2 plus Melphalan 140mg/m2:6; Fludarabine
plus Melphalan plus Antithymocyte Globulin:2; Fludarabine
180mg/m2 plus Bulsufan 10mg/m2 plus Antithymocyte
globulin 5mg/kg:1).
Results: In the myeloablative conditioning group (n¼5), all
the patients presented marrow engraftment; one relapsed.
Three patients presented grade II-IV acute graft versus host
disease, and four developed severe chronic graft versus host
disease. Four patients died, and the only survivor was 10
years-old. Median survival was 479 days. In RIC group (n¼9),
engraftment didn't occur in one patient (which had spleno-
megaly of 18 cm at the time of transplantation), and another
three relapsed. The other seven patients remained alive and
free of disease, with median survival of 750 days (34-1872;
P¼ 0,000123).
Conclusion: In spite of the limited number of patients in this
study, data suggest that RIC regimens improved survival in
HSCT for myeloﬁbrosis in our center, even with a slightely
greater relapse risk. Except for very young patients, this
strategy should be considered for further investigation.361
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is an established therapy for malignant and nonma-
lignant hematologic disorders. Reduced-intensity condi-
tioning (RIC) regimens have expanded the use of HSCT to the
elderly patients and to patients that are otherwise ineligible
for conventional transplants. However, RIC HSCT still
remains associated with a signiﬁcant morbidity and
mortality and the careful assessment of risks and beneﬁts
before transplantation is essential. Major factors which
inﬂuence non-relapse mortality (NRM) and overall survival
(OS) after HSCT are diagnosis, type of transplant and the
patient's risk proﬁle, which includes age and presence ofcomorbidities. The use of the hematopoietic cell trans-
plantation-speciﬁc comorbidity index (HSCT-CI) has been
proposed to predict the probability of non-relapse mortality
(NRM) and overall survival (OS) following HSCT. Since its
development, HSCT-CI has been evaluated at different insti-
tutions for various hematologic diseases. We performed
a single-center retrospective study to assess the prognostic
value of HSCT-CI on transplant outcomes in a cohort of
patients undergoing RIC HSCT. We analyze patients receiving
a RIC HSCT between January 2005 and December 2010. The
median patient age at the time of transplantation was 57
years (range: 19-75 years). The patient diagnoses included
AML (32%), NHL (28%), MM (15%), MDS (10%), HD (5%), CLL
(5%), ALL (3%), MPD (1%) and nonmalignant hematologic
(1%). The median pre-transplantation HSCT-CI score was 2
(range: 0-9). Among 133 patients, OS at 2 years was 36%. The
2 yr OS is 34%, 33% and 41% in the low-, intermediate-, and
high-risk HSCT-CI groups respectively (P ¼ .72). The corre-
sponding NRM at 2 years was 39%, 41% and 38% (P ¼ .85).
Further subgroup analysis (patient age, diagnosis, condi-
tioning, remission status and prior stem cell transplant)
disclosed no signiﬁcant differences in the OS prediction by
the HCT-CI score. In conclusion, we found no predictive value
of HSCT-CI for the determination of 2-year OS or 2-year NRM
in allogeneic HSCT receiving reduced-intensity condition.362
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Prolonged hospitalization exposes patients (pts) under-
going allogeneic hematopoietic cell transplantation (HCT) to
risks of iatrogenic complications and results in signiﬁcant
morbidity and mortality as well as expense, however, there
are limited data on risk factors that contribute to length of
stay (LOS) in HCT pts.
663 pts underwent HCT from 1/1997 to 12/2011. Among
663 pts, 49 died in the hospital within 6 weeks (wks) of
transplant and were excluded, leaving 614 pts, median age 44
(range 18-71 years), for analysis. Pts underwent HCT for acute
myeloid leukemia (n¼258), acute lymphoblastic leukemia
(n¼98), myelodysplastic syndrome (n¼87), chronic myeloid
leukemia (n¼78), non Hodgkin lymphoma (n¼55), aplastic
anemia (n¼20), Hodgkin disease, myeloproliferative
neoplasm, and plasma cell disorders (remaining n¼18). The
majority of pts underwent myeloablative transplant (n¼599,
97.6%); 15 (2.4%) had a reduced-intensity transplant. 317
(51.6%)pts receiveda transplant fromarelateddonor, 250 from
an unrelated donor (40.7%) and 47 (7.7%) received cord blood.
153 pts (25%) were identiﬁed to have a prolonged LOS,
deﬁned as 6 wks. In univariable analyses, variables asso-
ciated with LOS included: poor performance status (PS)
(odds ratio [OR] 1.31 per 10 point decrease on Karnofsky
scale, P ¼ .017), unrelated donor transplant (OR 3.45,
P < .001), cord blood transplant (OR 7.86, P < .001), HLA
mismatch (OR 4.45, P < .001), and CD34+ cell dose (median
